Neurocrine Biosciences(FRA) NB3

Market Cap€13.45B

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

€131.95

-0.27%

-0.35Today

Neurocrine Biosciences Financials at a Glance

Market Cap

€13.45B

Revenue (TTM)

€2.89K

Net Income (TTM)

€604.67

EPS (TTM)

€5.85

P/E Ratio

22.61

Dividend

€0.00

Beta (Volatility)

-0.04 (Low)

Dividend

€0.00

Beta (Volatility)

-0.04 (Low)

Price

€131.95

Volume

Open

€131.95

Price

€131.95

Volume

Open

€131.95

Previous Close

€131.95

Daily Range

€131.95 - €131.95

52-Week Range

€102.55 - €160.50

Estimated Earnings Date

N/A

Dividend

€0.00

Beta (Volatility)

-0.04 (Low)

Price

€131.95

Volume

Open

€131.95

Previous Close

€131.95

Daily Range

€131.95 - €131.95

52-Week Range

€102.55 - €160.50

Estimated Earnings Date

N/A

NB3 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops, and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Industry

Biotechnology

Sector

Health Care

Employees

2,000

CEO

Kyle W. Gano, PhD, MBA

Website

www.neurocrine.com

NB3 Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

21.88%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

4.42%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€13.45B

Shares Outstanding

101.65M

Volume

Avg. Volume

35.424

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Neurocrine Biosciences Performance Analysis

Neurocrine Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 1,416,495,129	47.7%
2023	2023-12-31	EUR 1,745,511,761	23.2%
2024	2024-12-31	EUR 2,177,424,542	24.7%
2025	2025-12-31	EUR 2,534,605,606	16.4%

Neurocrine Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR 1.49	92.0%
2023	2023-12-31	EUR 2.29	53.8%
2024	2024-12-31	EUR 3.04	33.1%
2025	2025-12-31	EUR 4.14	36.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€824.80

+1.4%

Gross Profit

€790.74

+1.3%

Gross Margin

95.87%

+1.0%

Market Cap

€13.45B

N/A

Market Cap/Employee

€7.43

N/A

Employees

2,000

N/A

Net Income

€124.19

+1.3%

EBITDA

€152.92

+1.1%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€642.18

+0.0%

Total Debt

€351.44

+0.8%

Accounts Receivable

€775.82

+1.5%

Inventory

€91.14

+1.9%

Long Term Debt

€351.44

+0.9%

Short Term Debt

€0.00

+0.0%

Return on Assets

15.11%

+1.5%

Return on Invested Capital

9.60%

+0.8%

Free Cash Flow

€61.10

+0.8%

Operating Cash Flow

€67.86

+0.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About NB3

What is the current price of Neurocrine Biosciences?

Neurocrine Biosciences is trading at €131.95 per share.

What is the 52-week range for Neurocrine Biosciences?

Over the past 52 weeks, Neurocrine Biosciences has traded between €102.55 and €160.50.

How much debt does Neurocrine Biosciences have?

As of the most recent reporting period, Neurocrine Biosciences reported total debt of €351.44M.

How much cash does Neurocrine Biosciences have on hand?

Neurocrine Biosciences reported €290.74M in cash and cash equivalents in its most recent financial results.

What is Neurocrine Biosciences’s dividend yield?

Neurocrine Biosciences does not currently have a dividend yield.

Neurocrine Biosciences(FRA) NB3

Neurocrine Biosciences Financials at a Glance

NB3 News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Neurocrine Biosciences

NB3 Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Neurocrine Biosciences Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NB3

What is the current price of Neurocrine Biosciences?

What is the 52-week range for Neurocrine Biosciences?

How much debt does Neurocrine Biosciences have?

How much cash does Neurocrine Biosciences have on hand?

What is Neurocrine Biosciences’s dividend yield?

Premium Investing Services